Hubei Daily (reporter Long Hua, correspondent Huang Shan) on December 21, according to the work deployment of the provincial Party committee and the provincial government and the work arrangement of the National Medical Insurance Bureau, our province took the lead in forming an inter provincial alliance with 18 provinces (cities, autonomous regions and Xinjiang production and construction Corps) such as Hebei, Shanxi and Inner Mongolia to hold a centralized procurement information disclosure conference in Han to jointly carry out the centralized procurement of Chinese patent medicines. Through on-site competition, 97 enterprises and 111 products were selected, and the average price of selected drugs decreased by 42.27% and the largest by 82.63%.

The covid-19 products are of the same specifications and are well chosen. Most of the mainstream products and new crown pneumonia treatment programs are selected in the current clinical practice, which can effectively meet the needs of clinical and normal epidemic prevention and control. According to the annual demand of 19 provinces (cities, autonomous regions and Xinjiang production and Construction Corps), it is estimated that the annual drug cost can be saved by more than 2.6 billion yuan. The price reduction effect of the centralized purchase of Chinese patent medicine alliance will radiate to the whole country, and the burden of patients’ drug expenses is expected to be further reduced.

It is understood that previously, six batches of drugs have been carried out by the state and multiple batches of drugs have been carried out by provinces (inter provincial alliance), mainly involving chemical drugs and biological drugs. In this regard, under the guidance of the National Medical Insurance Bureau, the Chinese patent medicine alliance carried out in-depth and detailed research and data analysis, optimized the rules in line with the market requirements, improved the quality first evaluation system, and explored and formed a centralized purchase mode in line with the characteristics and unique attributes of Chinese patent medicine.

According to the provincial medical insurance bureau, the Chinese patent medicine alliance will conduct centralized purchase of mainstream Chinese patent medicine varieties with large clinical use and high purchase amount, conduct comprehensive evaluation competition with price decline supplemented by clinical recognition, production and supply capacity, innovation ability, drug quality, bidding and purchase credit rating and other indicators, and set a “one vote veto” for quality problems. At present, the procurement results have been publicized. At the end of the publicity period, after the official results are announced, the alliance provinces will organize the implementation, so that people can cut into high-quality and affordable Chinese medicines.

Hubei Daily (reporter Long Hua, correspondent Huang Shan) on December 21, according to the work deployment of the provincial Party committee and the provincial government and the work arrangement of the National Medical Insurance Bureau, our province took the lead in forming an inter provincial alliance with 18 provinces (cities, autonomous regions and Xinjiang production and construction Corps) such as Hebei, Shanxi and Inner Mongolia to hold a centralized procurement information disclosure conference in Han to jointly carry out the centralized procurement of Chinese patent medicines. Through on-site competition, 97 enterprises and 111 products were selected, and the average price of selected drugs decreased by 42.27% and the largest by 82.63%.

The covid-19 products are of the same specifications and are well chosen. Most of the mainstream products and new crown pneumonia treatment programs are selected in the current clinical practice, which can effectively meet the needs of clinical and normal epidemic prevention and control. According to the annual demand of 19 provinces (cities, autonomous regions and Xinjiang production and Construction Corps), it is estimated that the annual drug cost can be saved by more than 2.6 billion yuan. The price reduction effect of the centralized purchase of Chinese patent medicine alliance will radiate to the whole country, and the burden of patients’ drug expenses is expected to be further reduced.

It is understood that previously, six batches of drugs have been carried out by the state and multiple batches of drugs have been carried out by provinces (inter provincial alliance), mainly involving chemical drugs and biological drugs. In this regard, under the guidance of the National Medical Insurance Bureau, the Chinese patent medicine alliance carried out in-depth and detailed research and data analysis, optimized the rules in line with the market requirements, improved the quality first evaluation system, and explored and formed a centralized purchase mode in line with the characteristics and unique attributes of Chinese patent medicine.

According to the provincial medical insurance bureau, the Chinese patent medicine alliance will conduct centralized purchase of mainstream Chinese patent medicine varieties with large clinical use and high purchase amount, conduct comprehensive evaluation competition with price decline supplemented by clinical recognition, production and supply capacity, innovation ability, drug quality, bidding and purchase credit rating and other indicators, and set a “one vote veto” for quality problems. At present, the procurement results have been publicized. At the end of the publicity period, after the official results are announced, the alliance provinces will organize the implementation, so that people can cut into high-quality and affordable Chinese medicines.